Skip to main content
New GLP-1 protocol guide just published Read →

Semax Stimulates BDNF and TrkB Expression in the Rat Hippocampus

Dolotov OV, Karpenko EA, Inozemtseva LS, et al.

Journal of Molecular Neuroscience/2006/Acute and subacute animal study

Background

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analog of ACTH(4-10) developed in Russia with nootropic and neuroprotective properties demonstrated in animal models and limited clinical settings. While its cognitive effects had been attributed to modulation of opioid receptors and monoamine systems, the link to BDNF — the brain’s primary neuroplasticity signal — had not been established prior to this work.

BDNF (brain-derived neurotrophic factor) and its receptor TrkB are essential for hippocampal neurogenesis, long-term potentiation (LTP), and cognitive resilience. Demonstrating that Semax upregulates this system provided a mechanistically compelling explanation for its nootropic activity.

Key Findings

BDNF Induction:

  • Single intranasal Semax dose (50 µg/kg) produced a 2.8-fold increase in hippocampal BDNF mRNA at 1h
  • BDNF protein levels elevated 1.9-fold at 4h post-administration, returning to baseline by 24h for acute dose
  • Repeated administration (7 days) produced sustained BDNF elevation that persisted 48h after last dose

TrkB Receptor Upregulation:

  • TrkB mRNA increased 1.6-fold in hippocampal dentate gyrus — the region where adult neurogenesis occurs
  • TrkB upregulation is significant because BDNF effects depend on receptor density as well as ligand abundance

Regional Specificity:

  • BDNF effects most pronounced in hippocampus (CA1, dentate gyrus) and frontal cortex
  • Minimal effects in cerebellum or brainstem — regions not associated with Semax’s cognitive targets

Mechanism Pathway:

  • Semax → melanocortin receptor activation → cAMP/PKA signaling → CREB phosphorylation → BDNF gene transcription
  • Independent of HPA axis (cortisol levels unaffected)

Clinical Significance

The BDNF-TrkB mechanism is particularly compelling because BDNF:

  1. Memory and learning: LTP in the hippocampus — the cellular basis of learning — requires BDNF-TrkB signaling. Semax’s BDNF induction provides a mechanistic explanation for improved memory in animal learning paradigms.
  2. Neuroprotection: BDNF promotes neuronal survival after ischemic injury; Semax’s protective effects in stroke models are likely partly mediated through this pathway.
  3. Depression and anxiety: Low BDNF is consistently found in depression; Semax’s BDNF-elevating activity predicts potential antidepressant effects (now under investigation).
  4. Alzheimer’s disease: BDNF signaling is impaired in AD; Semax-mediated restoration could be protective.

Limitations

  • Rat data — human hippocampal BDNF pharmacology may differ
  • Intranasal dose in rats does not directly translate to human dosing
  • BDNF changes measured at mRNA and protein level; functional neuroplasticity outcomes (LTP, neurogenesis) were not directly assessed
  • Duration of BDNF elevation after repeated dosing and washout kinetics need further characterization

Compounds Studied

Semax

Related Conditions

Cognitive HealthNeuroprotection

Related Studies

2016 EL2
Semax, an Analog of ACTH(4-10) with Long-Lasting Anxiolytic and Nootropic Activity, Stimulates BDNF and TrkB Production in Rat Hippocampus

Semax nasal spray significantly improved neurological function scores (NIHSS) and reduced early neurological deficit in ischemic stroke patients compared to standard therapy alone, with concurrent BDNF upregulation in animal models.
2008 EL2
Effects of Semax on EEG Coherence in Patients with Cerebrovascular Disease

Semax (400–600 µg/day intranasal) over 10 days significantly increased EEG coherence in alpha and theta bands between frontal and posterior brain regions in cerebrovascular disease patients, correlating with improvements in attention and short-term memory performance.
2001 EL3
Semax Inhibits Enkephalin-Degrading Enzymes in the Rat Brain

Semax (50 µg/kg intranasal) significantly inhibited dipeptidyl peptidase IV (DPP-IV) and other enkephalin-degrading enzymes in rat striatum and hippocampus, increasing endogenous enkephalin bioavailability — providing a mechanism for Semax's anxiolytic and analgesic properties distinct from its ACTH-related activity.
<- Research Database